Stroke:动脉闭塞对急性缺血性卒中后静脉溶栓效果的影响

2014-11-30 MedSci译 MedSci原创

我们计划通过研究急性缺血性卒中患者,评价其急性期头颈部CT血管造影进而了解静脉溶栓(IVT)和动脉闭塞之间的相互作用。 研究方法: 患者选自急性卒中注册表和洛桑分析(ASTRAL)注册表,发病到入院间隔时间≤4小时,进行急性期头颈部CT血管造影,发病前改良Rankin量表评分≤2,美国国立卫生研究院中风评分量表≤4。患有明显的颅内动脉阻塞(≥50%–99%)以及正在接受急性

我们计划通过研究急性缺血性卒中患者,评价其急性期头颈部CT血管造影进而了解静脉溶栓(IVT)和动脉闭塞之间的相互作用。



研究方法:

患者选自急性卒中注册表和洛桑分析(ASTRAL)注册表,发病到入院间隔时间≤4小时,进行急性期头颈部CT血管造影,发病前改良Rankin量表评分≤2,美国国立卫生研究院中风评分量表≤4。患有明显的颅内动脉阻塞(≥50%–99%)以及正在接受急性血管内治疗的患者被排除在外。一项对IVT交互性分析和原发性动脉闭塞3个月的预后情况(改良Rankin 量表 <3)是在调整潜在的混杂因素后所得出的。

研究结果:

在654位被选中的患者中,382位患者(58%)表现有动脉闭塞,其中263位患者(69%)接受了IVT。272位患者没有或存在极微小的闭塞,其中139位患者(51%)接受了IVT。在调整交互分析中,有趋势支持动脉闭塞组(odds ratio [OR]=3.97; 95% confidence interval [CI], 0.83–18.97; P=0.08)存在闭塞的患者(adjusted OR for favorable outcome, 3.01; 95% CI, 1.10–8.28)有相对较好的预后,而在没有或存在极微小闭塞的患者(OR, 0.76; 95% CI, 0.21–2.74)中没有明显效果。相反,在进行溶栓治疗时,闭塞患者相比没有或存在极微小闭塞的患者有相似的良好预后比例,但是在缺少溶栓治疗时,预后结果相对较差。



总结:

从这一针对急性脑缺血卒中连续患者的回顾性分析中,我们发现一个趋势,在有原发动脉闭塞的情况下应用IVT相比没有或存在极微小闭塞的情况能够获得更好的预后。然而,在应用随机对照实验证明之前,此信息不应该影响目前的溶栓决策。

原始出处:

Medlin F1, Amiguet M2, Vanacker P2, Michel P2.Influence of Arterial Occlusion on Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke.Stroke. 2014 Nov 25. pii: STROKEAHA.114.006408. [Epub ahead of print]

本文是MedSci原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!


您还可以这样阅读,更多资讯,请关注MedSci微信
  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892632, encodeId=ddc11892632cf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 12 03:00:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022175, encodeId=6a6c20221e515, content=<a href='/topic/show?id=cbec3334967' target=_blank style='color:#2F92EE;'>#动脉闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33349, encryptionId=cbec3334967, topicName=动脉闭塞)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Aug 29 13:00:00 CST 2015, time=2015-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697233, encodeId=d671169e233b0, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 16 03:00:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671183, encodeId=e3a016e118397, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Dec 06 14:00:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806000, encodeId=7bb818060006d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Dec 05 05:00:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892632, encodeId=ddc11892632cf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 12 03:00:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022175, encodeId=6a6c20221e515, content=<a href='/topic/show?id=cbec3334967' target=_blank style='color:#2F92EE;'>#动脉闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33349, encryptionId=cbec3334967, topicName=动脉闭塞)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Aug 29 13:00:00 CST 2015, time=2015-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697233, encodeId=d671169e233b0, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 16 03:00:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671183, encodeId=e3a016e118397, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Dec 06 14:00:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806000, encodeId=7bb818060006d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Dec 05 05:00:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892632, encodeId=ddc11892632cf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 12 03:00:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022175, encodeId=6a6c20221e515, content=<a href='/topic/show?id=cbec3334967' target=_blank style='color:#2F92EE;'>#动脉闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33349, encryptionId=cbec3334967, topicName=动脉闭塞)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Aug 29 13:00:00 CST 2015, time=2015-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697233, encodeId=d671169e233b0, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 16 03:00:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671183, encodeId=e3a016e118397, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Dec 06 14:00:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806000, encodeId=7bb818060006d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Dec 05 05:00:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]
    2015-04-16 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892632, encodeId=ddc11892632cf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 12 03:00:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022175, encodeId=6a6c20221e515, content=<a href='/topic/show?id=cbec3334967' target=_blank style='color:#2F92EE;'>#动脉闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33349, encryptionId=cbec3334967, topicName=动脉闭塞)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Aug 29 13:00:00 CST 2015, time=2015-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697233, encodeId=d671169e233b0, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 16 03:00:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671183, encodeId=e3a016e118397, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Dec 06 14:00:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806000, encodeId=7bb818060006d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Dec 05 05:00:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1892632, encodeId=ddc11892632cf, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 12 03:00:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022175, encodeId=6a6c20221e515, content=<a href='/topic/show?id=cbec3334967' target=_blank style='color:#2F92EE;'>#动脉闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33349, encryptionId=cbec3334967, topicName=动脉闭塞)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Aug 29 13:00:00 CST 2015, time=2015-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697233, encodeId=d671169e233b0, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 16 03:00:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671183, encodeId=e3a016e118397, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Dec 06 14:00:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806000, encodeId=7bb818060006d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Dec 05 05:00:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]

相关资讯

房颤患者在口服华法林过程中发生脑卒中 怎么办?

近期碰到一例患有多年房颤的病人口服华法林抗凝治疗,前几日出现四肢乏力麻木,行走受限,在急诊行头颅CT提示脑梗死可能。患者及家属颇感疑惑:“医生说华法林是预防脑梗的,已经服用华法林,为什么还会发生脑梗死?”许多患者都知道,房颤最大的危害在于脑卒中,防止脑卒中发生的关键在于根治房颤,因此,不少阵发和部分持续房颤患者行射频消融治疗。而对于已经持续多年的房颤患者而言,手术成功率较低,多数患者依赖于抗凝药物

Stroke:心房纤颤患者急性脑缺血性卒中后的抗血栓治疗

对于合并患有心房纤颤和缺血性卒中(IS)的患者,目前指南推荐仅以口服抗凝药物(OAC)作为IS的二级预防。在一个对患有急性缺血性卒中和心房纤颤的大规模前瞻性队列研究中,我们明确了出院时抗血栓形成方案与主要脑血管事件之间的相互关联。 研究方法: 这一前瞻性队列的连续性患者主要包含在安大略省中风注册表。我们用多变量COX比例风险模型来确定出院时抗血栓形成方案与死亡时间或因复发IS、

Stroke:阿替普酶在急性缺血性卒中发病6小时内对全因死亡率的影响(国际卒中试验-3)

通过静脉注射阿替普酶的快速溶栓治疗可以降低急性缺血性卒中后的致残率。在一项探索性分析中,我们调查相关患者在接受阿替普酶治疗后远期生存率是否存在不同。  研究方法: 在这个开放性治疗的、国际化、随机化、对照试验中,缺血性卒中患者被随机分配到两组,分别为6小时内开始接受静脉注射阿替普酶(0.9mg/kg)配合标准化治疗组(人数=1515)和单一进行标准化试验组(人数=1520

Circ CQO:心脏病发作、卒中后残疾:给予幸存者更多关怀

新近密歇根大学进行了一项在全国范围内具有代表性的研究,研究将心脏病发作及卒中发生后存活患者进行记录编号,结果显示这些患者躯体功能急剧减退,且随着时间的推延功能减退的程度逐渐叠加。心脏病发作和卒中与存活患者未来10年的自理功能快速减退有关,多数患者进行穿衣、沐浴、日常采购和管理财务等日常活动需人长期协助。卒中后存活患者还具有较高的抑郁和智力减退(包括记忆丧失)风险。研究结果发表于《循环:心血管质量与

Stroke:AHA指南推荐地中海饮食预防卒中

日前刊登在Stroke上的一项美国心脏学会/美国卒中学会(AHA/ASA)关于卒中一级预防的最新指南称,应鼓励人们调整生活方式,包括采用地中海饮食或防治高血压的饮食方法研究(DASH)饮食、参加体育锻炼、控制血压,以降低首次卒中的风险。 [pdf free] 这项声明旨在为医生和患者提供基于证据的、全面的预防卒中的方案。地中海和DASH饮食方案的特点是强调水果、蔬菜、全谷物、坚

新型溶栓药物desmoteplase出现转机 能改善缺血性卒中的预后

今年6月,灵北(Lundbeck)新一代溶栓药物去氨普酶(desmoteplase)首个III期研究(DIAS-3)失败,为该药临床项目的推进蒙上了阴影。此前,业界曾对该药寄予厚望,FDA也已授予该药快车道地位。近日,desmoteplase临床项目似乎迎来转机,采用新的分析方法发现,desmoteplase与较好的功能预后相关。新分析数据同时表明,检测早期缺血性损伤时,与电脑断层扫描(CT)相比